Pediatric Relapsing Polychondritis : Diagnosis and Management in a French Retrospective Study

NCT06019221 | Unknown

• 1 other identifier: 8783
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The incidence in pediatrics is very low (about 3.5 per million per year according to a 2015 study) and therefore the data on the pathology very poor, especially on the therapeutic level. Without appropriate treatment, the disabling sequelae, even involving the vital prognosis, are significant. However, in paediatrics, therapeutic habits have been extrapolated from adult data and lack precision. Existing treatments are almost composed of immunomodulatory and/or immunosuppressive treatments. Different therapeutic lines have been introduced over the years and a better understanding of the pathology. More recently, biotherapies have been introduced in this pathology, but data on their effectiveness remain limited. Data on the evolution under therapy in children are thus still poor. Complications related to the pathology that can jeopardize the vital prognosis and the response to treatment for this pathology deserve to be studied in order to be known and if possible avoided. The aim of the study is to describe French practices and compare the lines of treatment proposed for juvenile atrophic polychondritis.

Conditions

Relapsing Polychondritis

Keywords

Polychondritis; Relapsing Polychondritis; Pediatric Relapsing Polychondritis

Outcome Measures

Primary Outcomes (1)

• Therapeutic effectiveness of the various treatments proposed depending on the degree of initial clinical involvement

  The aim of this study is to bring together the experiences of the various reference and competence centers in France concerning the clinical presentation, management and follow-up of children with relapsing polychondritis.

  Files analysed retrospectively from from January 01, 2008 to December 31, 2022 will be examined

Eligibility Criteria

• Age: 1 Year - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Minor subject aged 1 to 17 years having atrophic polychondritis

You may qualify if:

• Minor subject aged 1 to 17 years
• Diagnosis of atrophic polychondritis between 01/01/2008 to 31/12/2022.
• Subject (and/or his parental authority) who has not expressed, after being informed, his opposition to the reuse of his data for the purposes of this research.

You may not qualify if:

• Subject (or his parents) having expressed his (their) opposition to participating in the study
• Associated pathologies that cannot be related to the diagnosis of atrophic polychondritis and whose prognosis can lead to biases in the efficacy and/or complications related to treatments.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Pédiatrie 1 - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Polychondritis, Relapsing

Condition Hierarchy (Ancestors)

Cartilage Diseases; Musculoskeletal Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases

Study Officials

• Ariane ZALOSZYC, MD

  University Hospitals of Strasbourg

  STUDY DIRECTOR

Central Study Contacts

Ariane ZALOSZYC, MD

CONTACT

33 3 88 12 77 42; ariane.zaloszyc@chru-strasbourg.fr

Sarah-Louisa MAHI, MD

CONTACT

33 3 88 12 77 42; sarah-louisa.mahi@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 24, 2023
• First Posted: August 31, 2023
• Study Start: February 18, 2023
• Primary Completion: January 18, 2024
• Study Completion: January 18, 2024
• Last Updated: November 2, 2023

Record last verified: 2023-08

Locations

FR (1)